HIGHLIGHTS
- who: Davide Vecchiotti and collaborators from the Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila have published the research work: Elevated NF-B/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer, in the Journal: Cells 2022, 11, x FOR PEER REVIEW of /2022/
- what: Given that SHh and NF-κB(p65) control genes that are involved in several altered processes in PCa, and that SHh is a transcriptional target of NF-κB(p65) , the authors investigate the role of the NF . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.